BML Capital Management’s Elevation Oncology ELEV Stock Holding History

BML Capital Management’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,890,434	Closed	-$2.16M	–	21
2025 Q2	$2.16M	Sell	5,890,434 -500	-0%	-$167	1.64%	14
2025 Q1	$1.53M	Buy	+5,890,934	New	+$3.36M	1.24%	14
2023 Q1	–	Sell	-39,963	Closed	-$38K	–	33
2022 Q4	$38K	Buy	+39,963	New	+$40.6K	0.04%	25

Other funds holding ELEV

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

BML Capital Management's ELEV Position: Q3 2025 in Review

BML Capital Management sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 5,890,434 shares — an estimated $2.16M sold.

BML Capital Management first reported a position in ELEV in Q4 2022 and held it in 3 quarters. The position peaked at $2.16M in Q2 2025. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

BML Capital Management reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
BML Capital Management sold 5,890,434 Elevation Oncology shares in Q3 2025, an estimated $2.16M.
BML Capital Management first reported a position in Elevation Oncology in Q4 2022 and held it in 3 quarters.
BML Capital Management's Elevation Oncology position peaked at $2.16M in Q2 2025.
1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on BML Capital Management's 13F filing for Q3 2025, filed 10 Nov 2025.